FOxTROT: Predictive effects of ERBB2 and ERBB3 on neoadjuvant panitumumab benefit in RAS/BRAF wild-type (-wt) locally advanced colon cancer (LACC).

Appleyard, J.W., Seligmann, J.F. orcid.org/0000-0003-4379-6005, Morton, D. et al. (10 more authors) (2026) FOxTROT: Predictive effects of ERBB2 and ERBB3 on neoadjuvant panitumumab benefit in RAS/BRAF wild-type (-wt) locally advanced colon cancer (LACC). In: Journal of Clinical Oncology. 2026 ASCO Gastrointestinal Cancers Symposium, 08-10 Jan 2026, San Francisco, CA. Vol. 44 (2_suppl). American Society of Clinical Oncology (ASCO), p. 17. ISSN: 0732-183X. EISSN: 1527-7755.

Metadata

Item Type: Conference abstract
Authors/Creators:
Dates:
  • Published (online): 12 January 2026
  • Published: 10 January 2026
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Funding Information:
Funder
Grant number
Yorkshire Cancer Research Account Ref: 2UOLEEDS
L386-RA/2015/R2/003
Cancer Research UK Supplier No: 138573
FOXTROT
Amgen Limited ***USE 819922***
None given
Date Deposited: 24 Mar 2026 11:56
Last Modified: 24 Mar 2026 11:57
Published Version: https://ascopubs.org/doi/10.1200/JCO.2026.44.2_sup...
Status: Published
Publisher: American Society of Clinical Oncology (ASCO)
Identification Number: 10.1200/jco.2026.44.2_suppl.17
Related URLs:
Open Archives Initiative ID (OAI ID):

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Export

Statistics

View Altmetric information about this item.


CORE (COnnecting REpositories)